CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC HUMAN

All Clinical Trials for Secretin Synthetic Human

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00036231 ↗	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction	Terminated	Repligen Corporation	Phase 3	2002-04-01	The purpose of the study is to determine the effect of multiple doses of secretin on autism.
NCT00036244 ↗	Synthetic Human Secretin in Children With Autism	Completed	Repligen Corporation	Phase 3	2002-04-01	The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	National Institute on Deafness and Other Communication Disorders (NIDCD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00216294 ↗	Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder	Completed	Repligen Corporation	Phase 2	2005-02-01	The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.
NCT00216294 ↗	Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder	Completed	Shekhar, Anantha M.D., Ph.D.	Phase 2	2005-02-01	The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.
NCT00216294 ↗	Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder	Completed	Indiana University School of Medicine	Phase 2	2005-02-01	The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.

Clinical Trial Conditions for Secretin Synthetic Human

Condition Name

Condition Name for Secretin Synthetic Human
Intervention	Trials
Autism	3
Chronic Pancreatitis	2
Acute Recurrent Pancreatitis	1
Intraductal Papillary Mucinous Neoplasms	1

Condition MeSH

Condition MeSH for Secretin Synthetic Human
Intervention	Trials
Pancreatitis	4
Autistic Disorder	3
Pancreatitis, Chronic	2
Disease	1

Clinical Trial Locations for Secretin Synthetic Human

Trials by Country

Trials by Country for Secretin Synthetic Human
Location	Trials
United States	21

Trials by US State

Trials by US State for Secretin Synthetic Human
Location	Trials
Massachusetts	4
Washington	2
Indiana	2
Colorado	2
New Hampshire	1

Clinical Trial Progress for Secretin Synthetic Human

Clinical Trial Phase

Clinical Trial Phase for Secretin Synthetic Human
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	2
Phase 1	3

Clinical Trial Status

Clinical Trial Status for Secretin Synthetic Human
Clinical Trial Phase	Trials
Completed	5
Terminated	4
Unknown status	1

Clinical Trial Sponsors for Secretin Synthetic Human

Sponsor Name

Sponsor Name for Secretin Synthetic Human
Sponsor	Trials
Repligen Corporation	4
Massachusetts General Hospital	3
ChiRhoClin, Inc.	2

Sponsor Type

Sponsor Type for Secretin Synthetic Human
Sponsor	Trials
Industry	6
Other	6
NIH	2

Synthetic Human Secretin: Clinical Trials, Market Analysis, and Projections

Introduction

Synthetic human secretin, a pure peptide hormone with an amino acid sequence identical to naturally occurring secretin, has been a subject of significant interest in medical research and the pharmaceutical market. This article delves into the current state of clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Acute Pancreatitis Studies

One of the notable clinical trials involving synthetic human secretin is the Phase II study aimed at establishing its efficacy in human acute pancreatitis. This study, known as the SNAP (Synthetic Human Secretin in Human Acute Pancreatitis) study, investigates the use of intravenous synthetic human secretin as a pharmacologic adjunct to modulate the severity of acute pancreatitis. Patients are divided into cohorts receiving different doses of synthetic human secretin, with a control group not receiving the drug. The primary objective is to evaluate the efficacy of synthetic human secretin in reducing the severity of acute pancreatitis[1].

Exocrine Pancreatic Insufficiency in Pediatric Patients

Another significant study focuses on identifying the role of exocrine pancreatic insufficiency in pediatric patients with abdominal pain undergoing upper endoscopy. This 3-year prospective study uses an endoscopic pancreatic function test (ePFT) with secretin to assess pancreatic function in children. The goal is to determine if exocrine pancreatic insufficiency is a contributing factor to recurrent abdominal pain in these patients[1].

Intraoperative Use

A clinical trial published on ClinicalTrials.gov examined the intraoperative use of secretin to reduce pancreatic fistula formation in patients undergoing pancreaticoduodenectomy or distal pancreatectomy. The results showed that while intraoperative secretin administration did not significantly reduce clinically significant pancreatic fistula formation overall, it may benefit patients with identified intra-operative leaks[1].

Market Analysis

Current Market Size and Growth

The global synthetic human secretin market has witnessed substantial growth in recent years. As of 2022, the market size was valued at USD 9.37 million and is projected to surpass USD 15.30 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.6%[3][5].

Market Segmentation

The market is segmented based on types, such as exocrine pancreas function testing and Zollinger-Ellison syndrome testing, and by end-users, including academics, hospitals, and clinics. The indirect tests segment is expected to expand at the fastest CAGR during the forecast period due to its availability in clinical settings[3][5].

Regional Analysis

North America is anticipated to dominate the global market, driven by the increasing prevalence of pancreatitis, which affects around 80,000 people in the US annually. The Middle East and Africa region is also expected to grow rapidly due to increasing hospitalizations from acute pancreatitis and pancreatic cancer, along with advances in diagnosis and critical care management[3][5].

Market Drivers and Opportunities

Growing Demand for Diagnostic Testing

The rising demand for diagnostic testing for pancreatic disorders is a significant driver for the synthetic human secretin market. As the incidence of pancreatitis and other pancreatic disorders increases, the need for accurate diagnostic tools, such as synthetic human secretin, also grows[3][5].

Technological Advancements

Technological advancements in the development of synthetic drugs and diagnostic tests are creating lucrative opportunities for market players. Innovations in endoscopic pancreatic function tests and other diagnostic technologies are expected to further boost the market[3].

Increasing Disposable Income

Global increases in disposable income are also contributing to market growth, as more people have the financial resources to seek advanced medical diagnostics and treatments[3][5].

Challenges and Limitations

Lack of Efficacy in Certain Conditions

Despite its potential, synthetic human secretin has shown limited efficacy in certain conditions. For example, a double-blind, placebo-controlled trial found that a single dose of synthetic human secretin was not effective in treating autism or pervasive developmental disorders[4].

Clinical Trial Outcomes

Some clinical trials have not shown significant benefits of synthetic human secretin in reducing complications such as pancreatic fistula formation, although there may be specific scenarios where it is beneficial[1].

Key Takeaways

• Market Growth: The global synthetic human secretin market is expected to grow from USD 9.37 million in 2022 to USD 15.30 million by 2031, with a CAGR of 5.6%.
• Diagnostic Use: Synthetic human secretin is primarily used for diagnosing pancreatic disorders such as chronic pancreatitis and Zollinger-Ellison syndrome.
• Regional Dominance: North America is projected to dominate the market, with the Middle East and Africa showing rapid growth.
• Technological Advancements: Innovations in diagnostic tests and synthetic drug development are key drivers for market growth.
• Clinical Trials: Ongoing clinical trials are exploring the efficacy of synthetic human secretin in various conditions, including acute pancreatitis and exocrine pancreatic insufficiency.

FAQs

What is synthetic human secretin used for?

Synthetic human secretin is used primarily for diagnosing pancreatic disorders such as chronic pancreatitis and Zollinger-Ellison syndrome. It is also being studied for its potential therapeutic benefits in conditions like acute pancreatitis[3][5].

What is the current market size of synthetic human secretin?

As of 2022, the global synthetic human secretin market size was valued at USD 9.37 million[3][5].

What is the projected growth rate of the synthetic human secretin market?

The market is expected to grow at a CAGR of 5.6% from 2022 to 2031, reaching USD 15.30 million by the end of 2031[3][5].

Which region dominates the synthetic human secretin market?

North America is projected to dominate the global market due to the high prevalence of pancreatitis in the region[3][5].

Is synthetic human secretin effective in treating autism?

No, a clinical trial found that a single dose of synthetic human secretin was not effective in treating autism or pervasive developmental disorders[4].

What are the key drivers for the growth of the synthetic human secretin market?

Key drivers include the growing demand for diagnostic testing for pancreatic disorders, technological advancements in synthetic drug development, and increasing global disposable income[3][5].

Sources

1. ChiRhoClin, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
2. Synthetic Human Secretin Sales Market Size, Scope And Forecast - Market Research Intellect
3. Global Synthetic Human Secretin Market to Surpass USD 15.30 Million by 2031 - Growth Market Reports
4. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder - PubMed
5. Global Synthetic Human Secretin Market to Surpass USD 15.30 Million by 2031 - PR Newswire